Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Non-cash Items (2020 - 2025)

Apellis Pharmaceuticals has reported Non-cash Items over the past 6 years, most recently at $32.3 million for Q4 2025.

  • Quarterly results put Non-cash Items at $32.3 million for Q4 2025, down 13.4% from a year ago — trailing twelve months through Dec 2025 was $32.3 million (down 13.4% YoY), and the annual figure for FY2025 was $32.3 million, down 13.4%.
  • Non-cash Items for Q4 2025 was $32.3 million at Apellis Pharmaceuticals, down from $37.3 million in the prior quarter.
  • Over the last five years, Non-cash Items for APLS hit a ceiling of $317.0 million in Q4 2022 and a floor of $32.3 million in Q4 2025.
  • Median Non-cash Items over the past 5 years was $253.9 million (2023), compared with a mean of $186.5 million.
  • Biggest five-year swings in Non-cash Items: soared 191.53% in 2021 and later tumbled 85.31% in 2024.
  • Apellis Pharmaceuticals' Non-cash Items stood at $291.8 million in 2021, then rose by 8.64% to $317.0 million in 2022, then fell by 19.9% to $253.9 million in 2023, then crashed by 85.31% to $37.3 million in 2024, then fell by 13.4% to $32.3 million in 2025.
  • The last three reported values for Non-cash Items were $32.3 million (Q4 2025), $37.3 million (Q4 2024), and $253.9 million (Q4 2023) per Business Quant data.